A Phase 1b Pharmacodynamic Study of Durvalumab (MEDI4736) in Patients With HER-2 Positive Metastatic Breast Cancer (MBC) Receiving Trastuzumab
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Durvalumab (Primary) ; Trastuzumab
- Indications Breast cancer
- Focus Adverse reactions
- 13 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 14 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated